Who is eligible for clinical trial NCT06744920?

Participants must meet the protocol's inclusion criteria for Generalized Myasthenia Gravis. The stated age range is 18 Years to 85 Years. Confirm all requirements with the study coordinator.

Does clinical trial NCT06744920 provide travel or cost reimbursement?

Check with the site coordinator at the participating facility for travel and lodging stipend availability, and for which routine-care costs are covered.

🏛️ Verified NIH Record • Updated 2026-07-28

A Study to Investigate the Efficacy, Safety and Tolerability of Remibrutinib Versus Placebo in Adult Patients With Generalized Myasthenia Gravis (NCT06744920)

A Randomized, Double-blind, Placebo-controlled Phase III Study to Evaluate the Efficacy, Safety, and Tolerability of Remibrutinib in Patients With Generalized Myasthenia Gravis, Followed by an Open-label Extension Phase

🟢 Recruiting Phase3 💊 Investigational Drug / Biologic Sponsor: Novartis Pharmaceuticals

🩺 Plain-English Summary (8th-Grade Level)

A study to evaluate the efficacy, safety and tolerability of Remibrutinib versus placebo in adult patients with Generalized Myasthenia Gravis who are on stable, standard-of-care (SOC) treatment.

Who can join: To join this study, participants generally need to meet the listed inclusion criteria (6 items) and avoid the listed exclusions (3 items).

Location: Neuromuscular Research Center — Phoenix, Arizona

Age range: 18 Years to 85 Years

🧪 Interventions in This Study

📋 "Do I Qualify?" — 1-Minute Self Screener

Instant Checklist

Check every box below. If you can check all of them, you may meet the study's basic screening requirements (final eligibility is confirmed by the site team).

Adult patients with gMG (age 18-85 years)
Confirmed diagnosis of Myasthenia Gravis Foundation of America (MGFA) Class II-IV gMG at screening and likely not in need of a respirator for the duration of the study, as judged by the Investigator
Documented evidence of positive serologic testing for AChR+ antibody or MuSK+ antibody at screening, OR seronegative for both AChR and MuSK antibodies at screening
Baseline MG-ADL score ≥ 6 with ≥ 50% of the total score due to non ocular symptoms
Participants who have been receiving a standard-of-care treatment as specified in the protocol
Able to safely swallow the study medication according to investigator clinical judgement based on a bedside swallowing test or another formal swallowing test in line with local practice, both at Screening and Baseline

Usually NOT eligible if any of the following apply:

Exclusion Criteria:
Prior to baseline have been treated with intravenous immunoglobulins or plasma exchange (IVIg/PLEX) in the past month, with rituximab in the past 6 months, eculizumab in the past 2 months, ravulizumab or other complement inhibitors in the past 3 months, efgartigimod or other anti-FcRn therapies in the past 3 months, or had a thymectomy in the past 6 months or a planned thymectomy during the trial period
Women of child bearing potential, defined as all women physiologically capable of becoming pregnant, from menarche until becoming post-menopausal, unless they are using highly effective methods of contraception during dosing and for 1 week after stopping of study treatment Other protocol-defined inclusion/exclusion criteria may apply.

🔍 Extracted verbatim from the official NIH eligibility criteria. Always confirm with the study coordinator.

📍 All Participating Trial Locations (130 Sites)

Showing the first 25 of 130 sites.

Neuromuscular Research Center — Phoenix, Arizona
Honor Health Research Institute — Scottsdale, Arizona
Fullerton Neuro and Headache Ctr — Fullerton, California
University Of Southern California — Los Angeles, California
Univ Cali Irvine ALS Neuromuscular — Orange, California
California Pacific Medical Center — Sacramento, California
Medstar Washington Hospital Center — Washington D.C., District of Columbia
SFM Clinical Research LLC — Boca Raton, Florida
Homestead Assoc In Research Inc — Homestead, Florida
Neurology Associates PA — Maitland, Florida
AdventHealth — Orlando, Florida
Neurological Services of Orlando PA — Orlando, Florida
University of Chicago Medical Centr — Chicago, Illinois
Mid Atlantic Epilepsy and Sleep Ctr — Bethesda, Maryland
Massachusetts General Hospital — Boston, Massachusetts
Michigan State University-Department of Neurology — East Lansing, Michigan
Dent Neurological Institute — Buffalo, New York
Univ of Cincinnati Medical Center — Cincinnati, Ohio
Cleveland Clinic Foundation — Cleveland, Ohio
University of Pittsburgh Medical Center — Pittsburgh, Pennsylvania
Houston Methodist Hospital — Houston, Texas
UT Health Science Center — Houston, Texas
University of WA Division of Cardio — Seattle, Washington
Center for Neurological Disorders G — Greenfield, Wisconsin
Novartis Investigative Site — Rosario, Santa Fe Province

📞 Contact the Study Coordinator

Phone: (888) 669-6682

Email: novartis.email@novartis.com

Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.

💰 Cost, Insurance & Patient Rights

100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
Voluntary Participation: You may withdraw at any time without affecting your standard medical care.

More studies in Generalized Myasthenia Gravis

Explore by condition: All Generalized Myasthenia Gravis clinical trials

💡 How to Participate

Check the checklist above to see if you may qualify.
Contact the study coordinator using the phone/email above.
Ask about the visit schedule, what is covered at no cost, and any travel support.
Confirm with your own doctor before making a decision.

🏛️ View Official NIH Record ↗